COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience
{{output}}
Substantial changes in the management of cancer patients have been required worldwide in response to the COVID-19 pandemic. Beyond the due details on the primitive cancer site and setting at diagnosis, these latter adaptions are most commonly exemplified by a ... ...
